11 – 15 February 2017 Sun, 12 February
Davos 2
08:00 – 09:30 Session 1: Atherosclerosis, Risk Factors
Chairs: B. Pitt, Ann Arbor and S. Yusuf, Hamilton
08:00 Inflammation in atherosclerosis – closing the translational gap P. Libby, Boston
08:22 The new ESC Guidelines on CVD Prevention 2016 M. F. Piepoli, Piacenza
08:44 The microbiom: A new theory of atherosclerosis T. F. Lüscher, Zurich
09:06 Diabetes and atherosclerosis F. Cosentino, Stockholm
09:30 – 10:00 Coffee

Davos 2
10:00 – 11:30 Session 2: Hypertension
Chairs: J. E. Deanfield, London and P. Libby, Boston
10:00 Retracing the history of major clinical trials M. A. Pfeffer, Boston
10:22 SPRINT: Blood pressure targets from a European perspective T. F. Lüscher, Zurich
10:44 HOPE 3: Impact of combined BP and lipid lowering in primary prevention S. Yusuf, Hamilton
11:06 Invasive therapy for treating hypertension F. Mahfoud, Homburg/Saar
12:00 – 13:15 Lunch / Satellite Symposium Sanofi (a lunch bag will be offered)
Chairs: S. Windecker, Berne and C. M. Schmied, Zurich

A new era in the management of hypercholesterolemia

12:00 Introduction S. Windecker, Berne
C. M. Schmied, Zurich
12:05 Effects of intensive LDL lowering on atherosclerosis: Evidence from intracoronary imaging L. Räber, Berne
12:25 PCSK9 inhibition: Expected impact on cardiovascular outcomes C. Müller, Basel
12:45 PCSK9 inhibitors: First experiences and clinical pearls I. Petrova Slater, Lugano
F. Mach, Geneva
13:05 Discussion and take-home message S. Windecker, Berne
C. M. Schmied, Zurich
12:00 – 13:15 Lunch / Satellite Symposium Servier (a lunch bag will be offered)
Chair: F. Ruschitzka, Zurich

Hypertension and dyslipidemia: a challenge at heart


12:00 Introduction F. Ruschitzka, Zurich
12:05 Cardiovascular diseases prevention: Why are blood pressure and lipids so relevant? F. Mach, Geneva
12:25 Benefits of combining blood pressure and lipid lowering agents in primary and secondary prevention S. Yusuf, Hamilton
12:45 Reaching the target: Are all treatments the same? F. Ruschitzka, Zurich
13:05 Discussion and take-home message F. Ruschitzka, Zurich
Davos 2
13:30 – 15:00 Session 3: Prevention
Chairs: A. L. Catapano, Milan and C. Bode, Freiburg
13:30 Lifetime risk and the guidelines: Do the recommendations translate into long-term management? J. E. Deanfield, London
13:52 Nutrition and CVD: Data from 17 countries on 150’000 people S. Yusuf, Hamilton
14:14 Smoking, smoking cessation and cardiovascular risk I. Sudano, Zurich
14:36 Genetics and CVD H. Schunkert, Munich
15:00 – 15:30 Coffee

15:00 – 16:30 Poster Session: Atherosclerosis, Risk Factors, Basic Science
Chair: F. Cosentino, Stockholm
15:30 – 16:30 Meet the Expert Session - Cardiovascular disease prevention in Europe and the US
Moderators: P. Libby, Boston and M. F. Piepoli, Piacenza
Cases: S. Brouwers, Zurich and M. Nägele, Zurich
15:30 – 16:30 Meet the Expert Session - Sports Cardiology: Exercise prescription in patients with heart disease
Moderators: A. la Gerche, Melbourne and S. Sharma, London
Cases: C. M. Schmied, Zurich and D. Niederseer, Zurich
15:30 – 16:30 Meet the Expert Session - Which target blood pressure for which patient?
Moderators: F. Mahfoud, Homburg/Saar and S. Yusuf, Hamilton
Cases: I. Sudano, Zurich and S. Winnik, Zurich
Davos 2
16:30 – 17:30 Session 4: Sports Cardiology
Chairs: M. F. Piepoli, Piacenza and C. M. Matter, Zurich
16:30 Current ECG guidelines in screening of athletes S. Sharma, London
16:50 Exercise recommendations for cardiovascular patients C. M. Schmied, Zurich
17:10 Imaging in the primary prevention of SCD in sports: The role of coronary CT and cardiac MRI A. la Gerche, Melbourne
Davos 1
16:30 – 17:30 Session 5: Cardiac Imaging
Chairs: F. C. Tanner, Zurich
16:30 The role of CMR in clinical cardiology R. Manka, Zurich
16:50 Hybrid imaging O. Gämperli, Zurich
17:10 Echo: From M-mode to strain imaging O. A. Smiseth, Oslo
17:30 – 18:00 Apéro Riche

only for participants of the satellite symposium

Davos 2
18:00 – 19:15 Satellite Symposium Bayer Schweiz AG
Chair: T. F. Lüscher, Zurich

State of evidence and evolving approaches for stroke prevention in atrial fibrillation

18:00 Introduction by the chairperson T. F. Lüscher, Zurich
18:05 Managing patients with atrial fibrillation today – implications of the PIONEER AF-PCI results with rivaroxaban C. Bode, Freiburg
18:25 Effective stroke prevention in atrial fibrillation: real-world evidence with rivaroxaban J. Steffel, Zurich
18:45 Current and future perspectives for antithrombotic therapy: Studies in TAVI and other diseases S. Windecker, Berne
19:05 Discussion and take-home message T. F. Lüscher, Zurich
19:20 – 20:15 Clinical Seminar: Cardiovascular Imaging: CMR, CT, Nuclear
Moderator: J. J. Bax, Leiden
Panel: O. Gämperli, Zurich and R. Manka, Zurich
19:20 – 20:15 Clinical Seminar: Challenges in adults with congenital heart disease
Moderator: J. E. Deanfield, London
Panel: M. Greutmann, Zurich and D. Tobler, Basel
19:20 – 20:15 Clinical Seminar: Patients with ICD and CRT: Troubleshooting
Panel: A. Breitenstein, Zurich and J. Steffel, Zurich